357 related articles for article (PubMed ID: 23678073)
1. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients.
Abate D; Saldan A; Mengoli C; Fiscon M; Silvestre C; Fallico L; Peracchi M; Furian L; Cusinato R; Bonfante L; Rossi B; Marchini F; Sgarabotto D; Rigotti P; Palù G
J Clin Microbiol; 2013 Aug; 51(8):2501-7. PubMed ID: 23678073
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Cytomegalovirus (CMV) Enzyme-Linked Immunosorbent Spot and CMV QuantiFERON Cell-Mediated Immune Assays in CMV-Seropositive and -Seronegative Pregnant and Nonpregnant Women.
Saldan A; Forner G; Mengoli C; Tinto D; Fallico L; Peracchi M; Gussetti N; Palù G; Abate D
J Clin Microbiol; 2016 May; 54(5):1352-6. PubMed ID: 26962091
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the T-SPOT.CMV interferon-γ release assay in renal transplant recipients: A single center cohort study.
Chanouzas D; Small A; Borrows R; Ball S
PLoS One; 2018; 13(3):e0193968. PubMed ID: 29558479
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients.
Lee H; Park KH; Ryu JH; Choi AR; Yu JH; Lim J; Han K; Kim SI; Yang CW; Chung BH; Oh EJ
PLoS One; 2017; 12(12):e0189488. PubMed ID: 29232714
[TBL] [Abstract][Full Text] [Related]
5. T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients.
Gliga S; Korth J; Krawczyk A; Wilde B; Horn PA; Witzke O; Lindemann M; Fiedler M
J Clin Virol; 2018 Aug; 105():91-96. PubMed ID: 29936407
[TBL] [Abstract][Full Text] [Related]
6. Optimization of interferon gamma ELISPOT assay to detect human cytomegalovirus specific T-cell responses in solid organ transplants.
Abate D; Saldan A; Forner G; Tinto D; Bianchin A; Palù G
J Virol Methods; 2014 Feb; 196():157-62. PubMed ID: 24216234
[TBL] [Abstract][Full Text] [Related]
7. CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor.
Schachtner T; Stein M; Reinke P
Transplantation; 2017 Oct; 101(10):e315-e325. PubMed ID: 28594749
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus (CMV) Enzyme-Linked Immunosorbent Spot Assay but Not CMV QuantiFERON Assay Is a Novel Biomarker To Determine Risk of Congenital CMV Infection in Pregnant Women.
Forner G; Saldan A; Mengoli C; Gussetti N; Palù G; Abate D
J Clin Microbiol; 2016 Aug; 54(8):2149-54. PubMed ID: 27280418
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of QuantiFERON-Cytomegalovirus Test in Management of Kidney Transplant Recipients.
Tarasewicz A; Dębska-Ślizień A; Rutkowski B
Transplant Proc; 2016 Jun; 48(5):1650-3. PubMed ID: 27496465
[TBL] [Abstract][Full Text] [Related]
11. Clinical validation of a novel enzyme-linked immunosorbent spot assay-based in vitro diagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study.
Banas B; Steubl D; Renders L; Chittka D; Banas MC; Wekerle T; Koch M; Witzke O; Mühlfeld A; Sommerer C; Habicht A; Hugo C; Hünig T; Lindemann M; Schmidt T; Rascle A; Barabas S; Deml L; Wagner R; Krämer BK; Krüger B
Transpl Int; 2018 Apr; 31(4):436-450. PubMed ID: 29284181
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic usefulness of the cytomegalovirus (CMV)-specific T cell-based assay for predicting CMV infection after kidney transplant.
Kim T; Lee HJ; Kim SM; Jung JH; Shin S; Kim YH; Sung H; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH; Han DJ
Korean J Intern Med; 2020 Mar; 35(2):438-448. PubMed ID: 29865778
[TBL] [Abstract][Full Text] [Related]
13. Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients.
Lúcia M; Crespo E; Melilli E; Cruzado JM; Luque S; Llaudó I; Niubó J; Torras J; Fernandez N; Grinyó JM; Bestard O
Clin Infect Dis; 2014 Dec; 59(11):1537-45. PubMed ID: 25048845
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Commercial QuantiFERON-CMV and Overlapping Peptide-based ELISPOT Assays for Predicting CMV Infection in Kidney Transplant Recipients.
Kwon JS; Kim T; Kim SM; Sung H; Shin S; Kim YH; Shin EC; Kim SH; Han DJ
Immune Netw; 2017 Oct; 17(5):317-325. PubMed ID: 29093653
[TBL] [Abstract][Full Text] [Related]
15. Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients.
Banas B; Böger CA; Lückhoff G; Krüger B; Barabas S; Batzilla J; Schemmerer M; Köstler J; Bendfeldt H; Rascle A; Wagner R; Deml L; Leicht J; Krämer BK
BMC Immunol; 2017 Mar; 18(1):15. PubMed ID: 28270092
[TBL] [Abstract][Full Text] [Related]
16. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.
El Haddad L; Ariza-Heredia E; Shah DP; Jiang Y; Blanchard T; Ghantoji SS; El Chaer F; El-Haddad D; Prayag A; Nesher L; Rezvani K; Shpall E; Chemaly RF
J Infect Dis; 2019 Feb; 219(6):898-907. PubMed ID: 30295846
[TBL] [Abstract][Full Text] [Related]
17. Pre-transplant assessment of CMV-specific immune response by Elispot assay in kidney transplant recipients.
Rittà M; Costa C; Sidoti F; Ballocco C; Ranghino A; Messina M; Biancone L; Cavallo R
New Microbiol; 2015 Jul; 38(3):329-35. PubMed ID: 26147141
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
[TBL] [Abstract][Full Text] [Related]
19. Enzyme-Linked Immunospot Assay as a Complementary Method to Assess and Monitor Cytomegalovirus Infection in Kidney Transplant Recipients on Pre-emptive Antiviral Therapy: A Single-Center Experience.
Favi E; Santangelo R; Iesari S; Morandi M; Marcovecchio GE; Trecarichi EM; Salerno MP; Ferraresso M; Citterio F; Romagnoli J
Transplant Proc; 2017 Oct; 49(8):1766-1772. PubMed ID: 28923622
[TBL] [Abstract][Full Text] [Related]
20. Identifying Cytomegalovirus Complications Using the Quantiferon-CMV Assay After Allogeneic Hematopoietic Stem Cell Transplantation.
Yong MK; Cameron PU; Slavin M; Morrissey CO; Bergin K; Spencer A; Ritchie D; Cheng AC; Samri A; Carcelain G; Autran B; Lewin SR
J Infect Dis; 2017 Jun; 215(11):1684-1694. PubMed ID: 28431019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
